Recent Publications from Ford Laboratory/Collaborators (2025-2018)

Heide Ford Bibliography

Rosenbaum SR, Hughes, CJ, Fields, KM, Purdy, SC, Gustafson, AL, Wolin, AR, Hampton, D, Turner, N, Ebmeier, C, Costello, JC, Ford HL (2024). An EYA3/NF-κB/CCL2 signaling axis suppresses cytotoxic NK cells in the pre-metastatic niche to promote triple negative breast cancer metastasis.

Purdy, SC and Ford, HL (2024). Remembering Hypoxia: Uncovering the long-term effects of transient oxygen deprivation on IFN signaling and progression of breast cancer. Commentary published in Cancer Research.

Gardner, L, Rossi, J, Armstrong, B, Muse, M, LaVeck, A, Ford, HL*, Zhao, R*, and Wang, X* (2024). Rational design of novel allosteric EYA2 inhibitors as potential therapeutics for multiple brain cancers. *co-corresponding authors

Hughes, CJ, Alderman, C, Gustafson, AL, Fields, K, Zhao, R, and Ford, HL (2024). All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.

Alderman, C, Hughes, CJ, Ebmeier, C, Ahn, N, Ford, HL, and Zhao (2024). Biochemical Characterization of the EYA and PP2A-B55α interaction.

Alderman, C, Krueger, A, Rossi, J, Ford, HL, and Zhao, R (2023). In Vitro Phosphatase Assays for the EYA2 Tyr Phosphatase in Protein Tyrosine Phosphatase for Methods in Molecular Biology.

Wolin, AR*, Vincent. MY*, Hotz T, Purdy, SC, Rosenbaum, SR, Hughes, CJ, Hsu, JY, Oliphant, MUJ, Armstrong, B, Wessells, V, Varella-Garcia, M, Galbraith, M, Pierce, A, Venkataraman, S, Danis, E, Veo, B, Serkova, N, Vibhakar, R, Ford, HL (2023). EYA2 Tyrosine Phosphatase Inhibition Reduces MYC and Prevents Medulloblastoma Progression.

Hughes, CJ, Fields, KM, Danis, E, Hsu, JY, Neelakantan, D, Vincent, MY, Gustafson, A, Oliphant, MUJ, Sreekanth, V, Zaberezhnyym V, Costello, JC, Jedlicka, P, and Ford, HL (2023). SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma.

Wilson C, Mertens TC, Shivshankar P, Bi W, Collum SD, Wareing N, Ko J, Weng T, Naikawadi RP, Wolters PJ, Maire P, Jyothula SS, Thandavarayan RA, Ren D, Elrod ND, Wagner EJ, Huang HJ, Dickey BF, Ford HL, Karmouty-Quintana H. Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosis.

Hsu JY, Danis EP, Nance S, O'Brien JH, Gustafson AL, Wessells VM, Goodspeed AE, Talbot JC, Amacher SL, Jedlicka P, Black JC, Costello JC, Durbin AD, Artinger KB, Ford HL. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.

Anantharajan J, Baburajendran N, Lin G, Loh YY, Xu W, Ahmad NHB, Liu S, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Hung AW, Joy J, Hill J, Ford HL, Zhao R, Keller TH, Kang C. Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Zhang G, Dong Z, Gimple RC, Wolin A, Wu Q, Qiu Z, Wood LM, Shen JZ, Jiang L, Zhao L, Lv D, Prager BC, Kim LJY, Wang X, Zhang L, Anderson RL, Moore JK, Bao S, Keller TH, Lin G, Kang C, Hamerlik P, Zhao R, Ford HL, Rich JN. Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe.

Kong, D*, Zhou H*, Neelakantan D, Hughes CJ, Hsu, JY, Srinivasan, RR, Lewis MT, and Ford, HL. VEGF-C Enhances Tumor Growth and Metastasis through Mediating Crosstalk Between EMT and Epithelial Breast Cancer cells.

Kong D, Hughes CJ, Ford HL. Cellular Plasticity in Breast Cancer Progression and Therapy. Front Mol Biosci.

Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MU, Ramirez D, Zhang L, Pineiro JT, Mathews Griner L, King R, Barnaeva E, Hu X, Southall NT, Ferrer M, Gustafson DL, Regan DP, D'Alessandro A, Costello JC, Patnaik S, Marugan J, Zhao R, Ford HL. A SIX1/EYA2 small molecule inhibitor disrupts EMT and metastasis.

Oliphant MUJ, Kong D, Zhou H, Lewis MT, Ford HL. Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis.

Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagué J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G; EMT International Association (TEMTIA). Guidelines and definitions for research on epithelial-mesenchymal transition.

Anantharajan J, Zhou H, Zhang L, Hotz T, Vincent MY, Blevins MA, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Baburajendran N, Lin G, Hung AW, Joy J, Patnaik S, Marugan J, Rudra P, Ghosh D, Hill J, Keller TH, Zhao R*, Ford HL*, Kang C*. Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.

Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL. SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program.

Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation'.

Guarnieri AL, Towers CG, Drasin DJ, Oliphant MUJ, Andrysik Z, Hotz TJ, Vartuli RL, Linklater ES, Pandey A, Khanal S, Espinosa JM, Ford HL. The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.